US regulator grants fast review for AZ ovarian cancer drugThe US Food and Drug Administration (FDA) has granted AstraZeneca priority review for its ovarian cancer drug Lynparza Share XUS regulator grants fast review for AZ ovarian cancer drughttps://pharmaphorum.com/news/us-regulator-grants-fast-review-for-az-ovarian-cancer-drug/
Diabetes drugs cost NHS more than £1bn a yearDiabetes prescriptions are costing the NHS in England more than £1 billion a year, driven by an increase Share XDiabetes drugs cost NHS more than £1bn a yearhttps://pharmaphorum.com/news/diabetes-drugs-cost-nhs-more-than-1bn-a-year/
Amazon sells exclusive diabetes and hypertension devicesAmazon has launched an exclusive range of medical devices to help people manage their diabetes and hypertension at Share XAmazon sells exclusive diabetes and hypertension deviceshttps://pharmaphorum.com/news/amazon-sells-exclusive-diabetes-and-hypertension-devices/
Sensyne’s gestational diabetes AI app launches on the NHSArtificial intelligence company Sensyne Health has launched a new app that helps women manage gestational diabetes, and five Share XSensyne’s gestational diabetes AI app launches on the NHShttps://pharmaphorum.com/news/sensynes-gestational-diabetes-ai-app-launches-on-the-nhs/
Lilly unveils promising data from dual-action diabetes drugEli Lilly’s investigational diabetes drug has shown early promise as a possible aid to overcoming obesity in trial Share XLilly unveils promising data from dual-action diabetes drughttps://pharmaphorum.com/news/lilly-diabetes-unveils-promising-data-from-dual-action-diabetes-drug/
Novo to market ‘connected’ insulin pens next yearNovo Nordisk is to launch “connected” insulin pens, responding for demands from patients for devices able to communicate Share XNovo to market ‘connected’ insulin pens next yearhttps://pharmaphorum.com/news/novo-to-market-connected-insulin-pens-next-year/
Roche buys Tusk, plus cancer immunotherapy drug, for £62mRoche has bought immuno-oncology biotech firm Tusk Therapeutics for an upfront payment of £62 million. Tusk’s shareholders will Share XRoche buys Tusk, plus cancer immunotherapy drug, for £62mhttps://pharmaphorum.com/news/roche-buys-tusk-plus-cancer-immunotherapy-drug-for-62m/
Roche Diabetes Care partners with digital therapeutics firm IesoRoche’s diabetes arm is working with Ieso Digital Health to test the Cambridge, UK-based digital therapeutics firm’s mental Share XRoche Diabetes Care partners with digital therapeutics firm Iesohttps://pharmaphorum.com/news/roche-diabetes-care-ieso-digital-health/
Study shows AZ’s Farxiga diabetes drug cuts heart risksAstraZeneca’s Farxiga has become the latest type 2 diabetes drug to show it can reduce cardiovascular risk in Share XStudy shows AZ’s Farxiga diabetes drug cuts heart riskshttps://pharmaphorum.com/news/study-shows-azs-farxiga-diabetes-drug-cuts-heart-risks/
